GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Enterprise Value
中文

Ocular Therapeutix (Ocular Therapeutix) Enterprise Value

: $630.72 Mil (As of Today)
View and export this data going back to 2014. Start your Free Trial

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ocular Therapeutix's Enterprise Value is $630.72 Mil. Ocular Therapeutix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-69.40 Mil. Therefore, Ocular Therapeutix's EV-to-EBIT ratio for today is -9.09.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Ocular Therapeutix's Enterprise Value is $630.72 Mil. Ocular Therapeutix's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-66.42 Mil. Therefore, Ocular Therapeutix's EV-to-EBITDA ratio for today is -9.50.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Ocular Therapeutix's Enterprise Value is $630.72 Mil. Ocular Therapeutix's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $58.44 Mil. Therefore, Ocular Therapeutix's EV-to-Revenue ratio for today is 10.79.


Ocular Therapeutix Enterprise Value Historical Data

The historical data trend for Ocular Therapeutix's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 203.72 1,403.51 429.64 178.92 400.32

Ocular Therapeutix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 178.92 394.10 407.01 221.82 400.32

Competitive Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix Enterprise Value Distribution

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Enterprise Value falls into.



Ocular Therapeutix Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Ocular Therapeutix's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Ocular Therapeutix's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocular Therapeutix  (NAS:OCUL) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Ocular Therapeutix's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=630.719/-69.4
=-9.09

Ocular Therapeutix's current Enterprise Value is $630.72 Mil.
Ocular Therapeutix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.40 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Ocular Therapeutix's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=630.719/-66.417
=-9.50

Ocular Therapeutix's current Enterprise Value is $630.72 Mil.
Ocular Therapeutix's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.42 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Ocular Therapeutix's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=630.719/58.442
=10.79

Ocular Therapeutix's current Enterprise Value is $630.72 Mil.
Ocular Therapeutix's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $58.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocular Therapeutix Enterprise Value Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix (Ocular Therapeutix) Business Description

Traded in Other Exchanges
Address
24 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Executives
Summer Road Llc 10 percent owner 207 6TH STREET, WEST PALM BEACH FL 33401
Antony C. Mattessich director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Rabia Gurses Ozden officer: Chief Medical Officer C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger officer: General Counsel 24 CROSBY DRIVE, BEDFORD MA 01730
Donald Notman officer: Chief Financial Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White officer: Chief Business Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Jeffrey S. Heier director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen officer: Chief Operations Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney director, 10 percent owner, officer: President and CEO C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730

Ocular Therapeutix (Ocular Therapeutix) Headlines

From GuruFocus

Ocular Therapeutix� To Report Third Quarter 2022 Financial Results

By Business Wire Business Wire 10-24-2022

Ocular Therapeutix� To Report Second Quarter 2022 Financial Results

By Business Wire Business Wire 07-25-2022

Insider Alert: An Insider Just Sold Ocular Therapeutix Inc Shares

By GuruFocus Research GuruFocus Editor 02-09-2023